US45826J1051 - Common Stock
INTELLIA THERAPEUTICS INC
NASDAQ:NTLA (4/19/2024, 7:07:12 PM)
After market: 21.57 0 (0%)21.57
+0.25 (+1.17%)
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. The company is headquartered in Cambridge, Massachusetts and currently employs 598 full-time employees. The company went IPO on 2016-05-06. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. The company is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE). The company is developing ex vivo applications to address immuno-oncology and autoimmune diseases. Its advanced ex vivo programs include a wholly owned chimeric antigen receptor T (CAR-T) cell candidate, NTLA-6001 targeting CD30 for the treatment of CD30-expressing hematologic cancers, including relapsed or refractory classical Hodgkin's lymphoma.
INTELLIA THERAPEUTICS INC
40 Erie St Ste 130
Cambridge MASSACHUSETTS 02139
P: 18572856200
CEO: John M. Leonard
Employees: 598
Website: https://www.intelliatx.com/
These stocks have plenty of catalysts ahead.
These two stocks could be ripe for a rebound.
These stocks, a bargain today, are players to hold on to for the long term.
Moderna and Intellia have declined in the double digits over the past year.
Biotech stocks can offer some of the best risk vs. reward payoff in the stock market. These three are ones to buy now.
Here you can normally see the latest stock twits on NTLA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: